Study Overview: This research is to check how well a new medicine called belzupacap sarotalocan (or bel-sar for short) works and how safe it is. It will be compared to a "sham" treatment, which is like a pretend treatment, in people with certain eye conditions. These conditions are called primary indeterminate lesions (IL) and small choroidal melanoma (CM), which are types of eye growths.

Treatment Process: Bel-sar is given through a special needle that injects the medicine into the eye, specifically in a part called the suprachoroidal space. After the medicine is given, a laser is used to activate it.

• Study Length: Participants should ask about the number and length of visits needed.
• Eligibility: Participants must have IL/CM, no spread of the disease, and not previously treated for these conditions.
• Risks: Possible risks include reactions to the medicine or laser and infections.

Participation: If you have the conditions mentioned and are interested, you could consider joining to help test this new treatment.